New treatment for lung cancer that targets mutant EGFR
Development of a first-in-class mEGFR dimerization inhibitor
This study is testing a new drug called DGD1202 that aims to help people with lung cancer by targeting a specific problem in cancer cells that have become resistant to current treatments, and it will be tested in lab-grown cancer cells and samples from patients to see how well it works and if it's safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10817896 on NIH RePORTER |
What this research studies
This research focuses on developing a novel drug, DGD1202, that inhibits the dimerization of mutant epidermal growth factor receptor (mtEGFR), which is often responsible for lung cancer. Current treatments, such as EGFR tyrosine kinase inhibitors, become ineffective after a short period due to resistance. DGD1202 aims to selectively kill cancer cells that have developed resistance to existing therapies by degrading the mtEGFR protein. The research involves testing this drug in various lung cancer cell lines and patient-derived xenografts to evaluate its effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients with mutant EGFR who have previously been treated with tyrosine kinase inhibitors.
Not a fit: Patients without mutant EGFR lung cancer or those who have not received prior treatment with EGFR inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for lung cancer patients who have become resistant to current therapies.
How similar studies have performed: Other research has shown promise in targeting mutant EGFR in lung cancer, but this specific approach with DGD1202 is novel.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Nyati, Mukesh K. — University of Michigan at Ann Arbor
- Study coordinator: Nyati, Mukesh K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.